2024
Synergistic Immunoregulation: harnessing CircRNAs and PiRNAs to Amplify PD-1/PD-L1 Inhibition Therapy
Han R, Rao X, Zhou H, Lu L. Synergistic Immunoregulation: harnessing CircRNAs and PiRNAs to Amplify PD-1/PD-L1 Inhibition Therapy. International Journal Of Nanomedicine 2024, 19: 4803-4834. PMID: 38828205, PMCID: PMC11144010, DOI: 10.2147/ijn.s461289.Peer-Reviewed Original ResearchConceptsRegulate PD-L1 expressionPD-L1 expressionPD-1/PD-L1Inhibition therapySensitive to immune checkpoint inhibitorsEfficacy of cancer immunotherapyPD-1/PD-L1 inhibitorsImmune checkpoint inhibitorsAnti-cancer immunityEfficacy of monotherapyExploration of combination strategiesModulate immune responsesMRNA vaccine technologyCheckpoint inhibitorsCancer immunotherapyRNA-based therapiesTreatment strategiesImmunomodulatory effectsCancer therapyImmune responseTherapyCancer treatmentVaccine technologyCombination strategiesCancer
1999
MYCOPHENOLATE MOFETIL MONOTHERAPY IN STABLE LIVER TRANSPLANT PATIENTS WITH CYCLOSPORINE-INDUCED RENAL IMPAIRMENT
Papatheodoridis G, O'Beirne J, Mistry P, Davidson B, Rolles K, Burroughs A. MYCOPHENOLATE MOFETIL MONOTHERAPY IN STABLE LIVER TRANSPLANT PATIENTS WITH CYCLOSPORINE-INDUCED RENAL IMPAIRMENT. Transplantation 1999, 68: 155-157. PMID: 10428285, DOI: 10.1097/00007890-199907150-00029.Peer-Reviewed Original ResearchConceptsStable liver transplant patientsLiver transplant patientsMajor side effectsTransplant patientsRenal impairmentMycophenolate mofetilSide effectsMycophenolate mofetil monotherapyReduction of cyclosporineSerum creatinine levelsEfficacy of monotherapyCellular rejectionIntravenous courseMaintenance immunosuppressantsMofetil monotherapyMycophenolate monotherapyCreatinine levelsSubtherapeutic levelsMonotherapyPatientsSignificant riskMonthsImpairmentMofetilCyclosporine
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply